SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAVAZZINI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.826
AS - Asia 7.896
EU - Europa 4.015
SA - Sud America 1.122
AF - Africa 175
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 27.062
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.543
SG - Singapore 2.999
CN - Cina 1.987
VN - Vietnam 887
DE - Germania 864
BR - Brasile 855
HK - Hong Kong 635
IT - Italia 611
UA - Ucraina 558
TR - Turchia 523
GB - Regno Unito 440
FI - Finlandia 335
FR - Francia 269
SE - Svezia 241
RU - Federazione Russa 227
JP - Giappone 199
IN - India 160
MX - Messico 137
PL - Polonia 121
CA - Canada 109
ID - Indonesia 96
AR - Argentina 92
BD - Bangladesh 92
ZA - Sudafrica 73
NL - Olanda 63
IQ - Iraq 62
EC - Ecuador 46
BE - Belgio 45
ES - Italia 44
CZ - Repubblica Ceca 42
PK - Pakistan 33
CO - Colombia 31
LT - Lituania 30
AT - Austria 29
SA - Arabia Saudita 28
VE - Venezuela 27
CL - Cile 26
UZ - Uzbekistan 26
MY - Malesia 23
MA - Marocco 21
PH - Filippine 20
TN - Tunisia 16
AU - Australia 15
KE - Kenya 15
NP - Nepal 15
AE - Emirati Arabi Uniti 14
EG - Egitto 14
IL - Israele 14
RO - Romania 13
DZ - Algeria 12
ET - Etiopia 11
PE - Perù 11
UY - Uruguay 11
BO - Bolivia 10
IE - Irlanda 10
JO - Giordania 10
PY - Paraguay 10
CH - Svizzera 9
DK - Danimarca 9
KR - Corea 9
DO - Repubblica Dominicana 8
TH - Thailandia 8
PS - Palestinian Territory 7
AL - Albania 6
BG - Bulgaria 6
HR - Croazia 6
OM - Oman 6
EU - Europa 5
IR - Iran 5
KZ - Kazakistan 5
LV - Lettonia 5
PT - Portogallo 5
QA - Qatar 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
BH - Bahrain 4
HU - Ungheria 4
LB - Libano 4
RS - Serbia 4
BY - Bielorussia 3
CR - Costa Rica 3
GR - Grecia 3
KG - Kirghizistan 3
LY - Libia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PA - Panama 3
SR - Suriname 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CI - Costa d'Avorio 2
EE - Estonia 2
GD - Grenada 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
LK - Sri Lanka 2
MT - Malta 2
NI - Nicaragua 2
PR - Porto Rico 2
Totale 27.030
Salva come PNG Salva come JPEG
Città #
Singapore 1.965
Ashburn 1.764
Woodbridge 1.238
Fairfield 1.181
Houston 835
Beijing 772
San Jose 700
Chandler 648
Jacksonville 627
Hong Kong 620
Santa Clara 594
Ann Arbor 487
Seattle 459
Wilmington 429
Cambridge 379
Ho Chi Minh City 277
Dallas 269
New York 258
Los Angeles 250
Izmir 229
Hanoi 201
Nanjing 199
Munich 192
Tokyo 184
Princeton 170
Ferrara 154
Lauterbourg 144
Helsinki 129
Boardman 120
Warsaw 117
San Diego 115
São Paulo 102
Shanghai 101
Council Bluffs 99
Addison 90
Turku 86
Mexico City 83
Milan 82
Orem 71
Shenyang 68
Jakarta 66
London 66
Nanchang 64
Da Nang 54
Chicago 53
The Dalles 47
Bremen 45
Chennai 45
Hebei 45
Brussels 43
Buffalo 43
Denver 43
Stockholm 42
Montreal 41
Rio de Janeiro 41
Johannesburg 39
Tianjin 39
Brooklyn 38
Haiphong 36
Hefei 36
Phoenix 36
Frankfurt am Main 34
Moscow 34
Falls Church 33
Atlanta 32
Columbus 32
Redwood City 32
Changsha 31
Jinan 31
San Francisco 31
Poplar 30
Boston 29
Falkenstein 29
Manchester 29
Jiaxing 28
Toronto 27
Rome 26
Baghdad 25
Brno 25
Guangzhou 25
Amsterdam 24
Mountain View 23
Zhengzhou 23
Dong Ket 22
Ankara 21
Dearborn 21
Mumbai 21
Biên Hòa 20
Nuremberg 20
Belo Horizonte 19
Des Moines 19
Norwalk 19
Tashkent 18
Quito 17
Salt Lake City 17
Fidenza 16
Guayaquil 16
Curitiba 15
Kunming 15
Lahore 15
Totale 18.394
Salva come PNG Salva come JPEG
Nome #
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 310
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 284
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 282
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 270
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 268
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 264
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 263
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 262
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 259
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 257
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 257
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 254
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 248
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 247
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 246
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 240
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 236
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 235
Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features 232
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 225
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 225
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 225
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 225
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 219
Secondary chromosome changes in mantle cell lymphoma: Cytogenetic and fluorescence in situ hybridization studies 218
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 218
Angiogenesis in multiple myeloma: Correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features 216
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 216
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival 215
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 215
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 215
Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. 214
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 214
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 214
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters 214
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 212
Alterazioni cromosomiche in cellule staminali emopoietiche indotte da esposizioni ambientali o professionali. 211
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors 211
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line 208
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 207
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 206
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases 204
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party 204
Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21 203
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 199
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS 197
Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia 194
In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome 194
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia” 193
Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome 190
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 190
Hepatosplenic T-cell lymphoma (HSTCL). 189
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance 187
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated with Ibrutinib 186
Multilineage involvement in the 5q- syndrome: A fluorescent in situ hybridization study on bone marrow smears 185
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 185
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 185
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 184
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 183
Differences among young adults, adults and elderly chronic myeloid leukemia patients 183
LATE APPEARANCE of 14q32/IGH TRANSLOCATION In CHRONIC LYMPHOCYTIC LEUKEMIA. 181
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 180
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 178
Intestinal T-cell lymphoma 176
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 173
Neoplastic circulating endothelial cells in hematologic malignancies 173
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study 172
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 172
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 170
Clinicobiological features in chronic lymphocytic leukemia with 14q32/IgH translocations. 170
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 170
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 168
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 168
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 166
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia 166
Essential Thrombocythemia (ET) 159
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 157
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 157
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia 155
Molecular cytogenetic lesions in chronic lymphocytic leukemia 155
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13) PDGFRB-NDE1 fusion 153
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA 153
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY? 152
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB 151
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 150
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results 150
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. 149
IN CHRONIC LYMPHOCYTIC LEUKEMIA THE AMOUNT OF PROLIFERATION CENTERS IN TISSUE-BIOPSIES CORRELATES WITH UNFAVORABLE CYTOGENETIC ABNORMALITIES 147
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 146
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. 145
Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. 144
First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era 143
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements 142
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients. 142
Capitolo 1. Fisiopatologia del sangue e degli organi ematopoietici. 142
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB 140
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia 139
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia (letter) 139
Imatinib In Very Elderly CML Patients: What Can We Achieve? 138
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 137
Totale 19.560
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.245
Totale 126.810
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021908 0 0 0 0 0 0 0 0 0 322 396 190
2021/20221.647 129 188 54 59 84 112 93 97 44 137 163 487
2022/20231.579 180 88 64 182 259 209 74 167 210 7 89 50
2023/2024780 79 91 37 18 38 143 42 54 24 16 26 212
2024/20253.717 94 102 273 101 488 363 68 149 648 406 510 515
2025/202610.564 993 566 907 1.465 1.626 782 1.296 699 1.162 1.068 0 0
Totale 27.390